SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($2.21), $0.36 worse than the analyst estimate of ($1.85). Revenue for the quarter came in at $1.44 million versus the consensus estimate of $1.96 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.